Elevance Health (NYSE:ELV) Updates FY 2026 Earnings Guidance

Elevance Health (NYSE:ELV) updated its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 27.000- for the period, compared to the consensus EPS estimate of 26.890. The company issued revenue guidance of -.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and raised their target price for the stock from $363.00 to $498.00 in a research report on Wednesday, May 20th. Cantor Fitzgerald upped their price target on shares of Elevance Health from $400.00 to $450.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Truist Financial increased their price objective on shares of Elevance Health from $450.00 to $475.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Wall Street Zen downgraded shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, TD Cowen boosted their target price on shares of Elevance Health from $400.00 to $465.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Fifteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $440.90.

Elevance Health Stock Performance

NYSE:ELV opened at $375.44 on Friday. The stock has a 50-day simple moving average of $397.01 and a two-hundred day simple moving average of $356.81. Elevance Health has a 52-week low of $273.71 and a 52-week high of $436.24. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.52. The firm has a market capitalization of $81.42 billion, a PE ratio of 16.69, a P/E/G ratio of 2.16 and a beta of 0.67.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 EPS for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The business had revenue of $49.83 billion during the quarter, compared to analysts’ expectations of $48.88 billion. During the same quarter in the prior year, the business posted $8.84 earnings per share. The business’s quarterly revenue was up .8% on a year-over-year basis. Analysts forecast that Elevance Health will post 27.07 EPS for the current year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s dividend payout ratio (DPR) is presently 30.58%.

Insiders Place Their Bets

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.34% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Compound Planning Inc. raised its holdings in Elevance Health by 19.9% during the fourth quarter. Compound Planning Inc. now owns 1,060 shares of the company’s stock valued at $372,000 after acquiring an additional 176 shares during the period. Claris Financial LLC bought a new position in shares of Elevance Health in the fourth quarter worth about $358,000. Axxcess Wealth Management LLC grew its position in shares of Elevance Health by 27.8% during the fourth quarter. Axxcess Wealth Management LLC now owns 1,767 shares of the company’s stock worth $619,000 after purchasing an additional 384 shares in the last quarter. Corient Private Wealth LLC grew its position in shares of Elevance Health by 45.7% during the fourth quarter. Corient Private Wealth LLC now owns 87,355 shares of the company’s stock worth $30,622,000 after purchasing an additional 27,409 shares in the last quarter. Finally, Alberta Investment Management Corp raised its stake in Elevance Health by 63.8% during the 4th quarter. Alberta Investment Management Corp now owns 17,200 shares of the company’s stock valued at $6,029,000 after purchasing an additional 6,700 shares during the period. Hedge funds and other institutional investors own 89.24% of the company’s stock.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.